How is Chikungunya virus infection diagnosed, treated, and prevented?

Chikungunya Virus: Diagnosis, Treatment, and Prevention

Diagnostic Approach

For acute Chikungunya infection, perform PCR or viral culture during the first 5 days of symptoms, then switch to IgM/IgG serology from day 5-7 onwards for later-stage diagnosis. 1

Molecular Testing (Days 1-5)

• PCR or viral culture is most effective during the first 5-7 days of symptoms when viremia is highest 1
• Nucleic acid amplification testing should be performed on serum collected within the first week of illness 1
• Viral culture can be attempted during this acute viremic phase but is less practical than PCR in most clinical settings 2

Serologic Testing (Day 5 Onwards)

• IgM antibodies against Chikungunya become detectable from day 6 onwards and serve as the primary diagnostic method for later presentations 3, 1
• IgG serology can be used in conjunction with IgM for confirmation 1
• Cross-reactivity with other alphaviruses (particularly O'nyong-nyong virus) must be considered when interpreting serologic results 2

Clinical Diagnostic Criteria

• Suspect Chikungunya in patients presenting with abrupt onset of high fever (after 5-7 day incubation, range 2-12 days) plus severe polyarthralgia/polyarthritis affecting hands, wrists, ankles, and metatarsal-phalangeal joints 1
• Accompanying features include constitutional symptoms and rash lasting 1-7 days 1
• The disease is almost always self-limiting and rarely fatal in uncomplicated cases 1

Treatment Approach

There is no specific antiviral therapy for Chikungunya; treatment is entirely supportive with acetaminophen for symptom relief and avoidance of NSAIDs/aspirin until dengue is excluded. 3, 4

Symptomatic Management

• Acetaminophen at standard doses is the exclusive analgesic recommended for pain and fever relief 3
• Never use aspirin or NSAIDs when dengue cannot be excluded due to increased bleeding risk and platelet dysfunction 3
• Ensure adequate oral hydration throughout the illness 3

Special Populations

• Acetaminophen remains the safest analgesic option for pregnant women with Chikungunya 3
• In children, acetaminophen dosing must be carefully calculated based on weight 3

Monitoring for Severe Disease

• Neurological complications occur primarily in infants <1 year old and adults >60 years, with a 10% case fatality rate among patients with neurological presentation 5, 1
• Watch for encephalitis, encephalopathy, Guillain-Barré syndrome, acute disseminated encephalomyelitis, and febrile seizures 5, 1
• In adults, neurological disease is more severe than in infants, with only 40% achieving apparent full recovery at 3 years post-discharge 5
• In infants, long-term sequelae include cerebral palsy and low developmental quotient 5, 1

Chronic Disease Management

More than 30% of infected individuals will develop chronic disease with persistent severe joint pain, tenosynovitis, and incapacitating polyarthralgia lasting months to years. 6

• Chronic disabling arthritis of the joints is the most common long-term complication 5
• This chronic arthritis negatively impacts quality of life and socioeconomic productivity 6, 7
• No specific therapies exist for chronic Chikungunya arthropathy; management remains supportive 4, 7

Prevention Strategies

Prevention depends entirely on mosquito vector control and personal protective measures to avoid Aedes mosquito bites, as no licensed vaccine or specific antiviral exists. 4, 7

Vector Control

• Target Aedes aegypti and Aedes albopictus mosquitoes, which are the primary vectors 5, 2, 8
• Implement surveillance programs for early outbreak identification 4
• Conduct vector control measures in endemic and outbreak areas 4, 7

Personal Protection

• Avoid mosquito bites in endemic countries through use of repellents, protective clothing, and bed nets 2
• Be particularly vigilant during daytime hours when Aedes mosquitoes are most active 8

Surveillance

• Early identification of outbreaks is critical for prevention and control 4
• Maintain high clinical suspicion in patients with compatible symptoms returning from epidemic/endemic areas 2, 4
• Consider Chikungunya in sporadic cases epidemiologically linked to ongoing local or international outbreaks 4

Critical Pitfalls to Avoid

• Do not misdiagnose Chikungunya as dengue due to similarities in clinical presentation, limited awareness, and overlapping geographic distribution 4
• Do not use NSAIDs or aspirin for symptom relief until dengue co-infection is definitively excluded 3
• Do not delay PCR testing beyond day 5 of symptoms, as sensitivity drops significantly after the acute viremic phase 1
• Do not dismiss the possibility of severe neurological complications in high-risk groups (infants <1 year, adults >60 years) 5, 1
• Do not underestimate the burden of chronic arthropathy, which affects more than 30% of patients and can persist for years 6